RKDANasdaqCrude Petroleum & Natural GasFiscal year ends December 31
Arcadia Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.14−0.02 (-12.01%)
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.3350 (−97.35%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Arcadia Biosciences, Inc. saw revenue fall 12.2% to $4.75M over the twelve months to Jun 30, 2026. Free cash flow was -$4.70M.
Revenue
$4.75M
-12.2% vs. a year earlier
Operating income
-$3.80M
TTM Q2 2026
Free cash flow
-$4.70M
FY2025
EPS, diluted
-$4.55
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $433.92K
- P/E ratio
- –
- Price to sales
- 0.09
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1083.15%
Fundamentals
- Revenue
- $4.75M
- Net income
- -$11.13M
- EPS, diluted
- -$4.55
- Free cash flow
- -$4.70M
- Diluted shares
- 3M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$4.75M-12.2% YoY
Gross profit
$1.64M-19.7% YoY
Operating income
-$3.80M
Net income
-$11.13M
EPS, diluted
-$4.55
Free cash flow
–
Reported periodTrailing twelve months